NewAmsterdam Pharma Company NV has published a document analyzing the impact of Obicetrapib on major adverse cardiovascular events. The document provides a pooled analysis of phase 3 clinical trials, focusing on patients treated with Obicetrapib compared to placebo over 12 months. It discusses the role of cholesteryl ester transfer protein (CETP) in lipid metabolism and the effects of Obicetrapib as a CETP inhibitor on lipid levels and cardiovascular risk. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on September 01, 2025, and is solely responsible for the information contained therein.